Privately-owned Prosensa Therapeutics BV of the Netherlands has raised €23 million to support its pipeline which includes a Phase 3 RNA-modulating therapeutic for Duchenne muscular dystrophy. New Enterprise Associates Inc led the financing. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
